Acrivon Therapeutics, Inc. Common Stock

of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934

of this Current Report on Form 8-K. The information set forth under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and

Other Events On January 8, 2026, the Company announced the following clinical data: ACR-368: Potential First-in-Class CHK1 / CHK2 Inhibitor • In Arm 1 of the AC

Financial Statements and Exhibits. Exhibit Number Description 99.1 January 8, 2025, Press Release 104 Cover Page Interactive Data File (embedded within the Inli